$3.61
0.1651[4.79%]
At close: Apr 24
$3.61
0[0.00%]
After Hours: 8:54AM EDT
Latest News for Genfit Stock (NASDAQ:GNFT)
Genfit Stock (NASDAQ: GNFT)
Categories: All
Friday, April 05, 2024
Thursday, April 04, 2024
- Genfit FY23 EPS $(0.62) Down From $(0.49) YoY, Sales $41.09M Up From $27.12M YoYBenzinga Newsdesk - Apr 4, 2024, 6:03PM
- GENFIT FY23 EPS €(0.58) Vs €(0.48) YoY; Revenue €38.176 Million Vs €26,566 Million YoYBenzinga Newsdesk - Apr 4, 2024, 4:13PM
- Earnings Scheduled For April 4, 2024Benzinga Insights - Apr 4, 2024, 5:18AM
Thursday, February 29, 2024
Friday, December 08, 2023
Thursday, December 07, 2023
Wednesday, December 06, 2023
Tuesday, November 14, 2023
Tuesday, September 26, 2023
Thursday, September 21, 2023
Wednesday, September 20, 2023
Thursday, July 13, 2023
Monday, July 03, 2023
Friday, June 30, 2023
- Genfit's Miss Is CymaBay Therapeutics' Gain: Analyst Says Rival Data Leaves Room for Seladelpar To Emerge As Best-In-ClassVandana Singh - Jun 30, 2023, 2:51PM
- Ipsen, Genfit's Elafibranor Shows Promise In Primary Biliary Cholangitis PatientsVandana Singh - Jun 30, 2023, 2:03PM
- 12 Health Care Stocks Moving In Friday's Intraday SessionBenzinga Insights - Jun 30, 2023, 1:37PM
- Why Renalytix Are Trading Higher By Over 48%; Here Are 20 Stocks Moving PremarketLisa Levin - Jun 30, 2023, 8:12AM
- Genfit shares are trading higher after the company with its partner Ipsen said ELATIVE Phase 3 trial of elafibranor for primary biliary cholangitis met its primary endpoint.Benzinga Newsdesk - Jun 30, 2023, 6:34AM
- Ipsen And Genfit Announced Topline Data From The Pivotal ELATIVE Phase 3 Trial, Of Elafibrano For Primary Biliary Cholangitis; The Trial Met Its Primary Composite Endpoint, With 51% Of Patients Achieving Cholestasis Response Compared With 4% On PlaceboBenzinga Newsdesk - Jun 30, 2023, 6:18AM
Thursday, June 22, 2023
Thursday, June 01, 2023
Wednesday, May 24, 2023
Monday, May 22, 2023
Monday, April 17, 2023
Thursday, April 13, 2023
Monday, October 10, 2022
Wednesday, September 28, 2022
Thursday, September 22, 2022
Monday, September 19, 2022
Wednesday, September 14, 2022
Tuesday, September 13, 2022
- Important Biotech Catalysts For September 13, 2022 - End Of The Day SummaryRagothaman Srinivasan - Sep 13, 2022, 6:45PM
- GENFIT Gets FDA Orphan Drug Status For Liver Disease CandidateRagothaman Srinivasan - Sep 13, 2022, 5:18PM
- GENFIT Announces FDA Has Granted Orphan Drug Designation To GNS5611, For The Treatment Of CholangiocarcinomaBenzinga Newsdesk - Sep 13, 2022, 4:12PM